Affiliate disclosure: This article contains Amazon affiliate links. As an Amazon Associate, Glowstice earns from qualifying purchases — at no extra cost to you. Our editorial recommendations are independent of these partnerships. Learn more.
PDRN has been one of the fastest-growing search terms in skincare for two years, and the site covers it in depth. What has happened more recently is that a second, closely related molecule — polynucleotide, or PN — has become the dominant injectable skin booster in Korean clinics, and the two names are now used interchangeably in consumer marketing despite describing meaningfully different things. The distinction is worth understanding, and so is the much larger gap between what either does by injection and what either does in a cream.
Why These Two Get Confused
Both are DNA-derived biopolymers sourced from salmon or trout. Both are used for what Korean aesthetics calls skin boosting. Both are marketed with near-identical language about regeneration. And the acronyms are one letter apart in a category where most consumers are encountering the concept for the first time.
The review literature has actually had to address this directly — there are published papers specifically bridging the definitional gap between PDRNs and PNs, which is a reasonable signal that even the clinical field found the terminology muddled.
Rejuran, launched in 2014, was the first polynucleotide product used as a skin booster, and it became well known enough that 'Rejuran' now functions as a genericised name for the whole PN category in the way Botox does for neuromodulators. Most consumer confusion traces back to that.
The Actual Molecular Difference
The difference is molecular weight and source tissue, and it has real consequences.
PDRN — polydeoxyribonucleotide — is a mixture of relatively low molecular weight DNA fragments, typically derived from salmon or trout sperm DNA. Shorter chains.
PN — polynucleotide — is a high molecular weight DNA chain, typically derived from salmon or trout gonads. Longer chains, and critically, chains long enough to behave differently as a material.
That length difference produces the property clinics actually care about: PN is substantially more viscoelastic than PDRN. Long chains entangle into a three-dimensional porous structure in the tissue, which means a PN injection provides physical scaffolding and persists longer at the site. PDRN, being shorter fragments, does not form that structure.
So the shorthand used in Korean practice is roughly: PDRN acts primarily as a biochemical signal, PN acts as a biochemical signal plus a structural support. That is why PN overtook PDRN as the preferred skin booster for general rejuvenation while PDRN retained its place in wound healing and specific regenerative applications.
Related Reading
Editor's Product Picks
Affiliate links — we earn a small commission at no extra cost to you.
Two Different Mechanisms
PDRN's best-characterised mechanism is adenosine receptor activation — specifically the A2A receptor. Its short oligonucleotide fragments act as a source of nucleosides that engage that pathway, which is associated with reduced inflammatory signalling and stimulation of tissue repair. This is the same receptor family discussed in our adenosine guide, which is a genuinely interesting convergence: two of K-beauty's signature ingredients act on the same signalling system.
PN shares the biostimulation of dermal fibroblasts, but adds the properties that come from being a long-chain biopolymer: high water-attracting and water-retaining capacity, and the porous three-dimensional structure described above. In practice this means PN is doing something closer to what a hyaluronic acid filler does mechanically, alongside the biological signalling.
Both are natural biopolymers with good biocompatibility, which is a large part of why they have been adopted so readily — the safety profile in the published work has been favourable, and that matters for an injectable used cosmetically.
The Injectable Evidence
The evidence base here is genuine, growing, and specifically about injection.
There are narrative reviews of PN and PDRN in dermatology, comparative analyses of their molecular mechanisms and clinical applications, real-life assessments of high-purification injectable PN for skin rejuvenation, and prospective observational work on PN injections for periorbital rhytides. A survey of Korean dermatologists documented the pattern of practice around injectable polynucleotide, which is itself a useful marker of how established this has become clinically.
What the literature also says plainly: the increasing clinical use of PN-based injectables makes generating real-world evidence essential. That is the standard phrasing for an intervention that is widely adopted and still accumulating its evidence base — which is an accurate description of where this sits. It is not a fringe treatment and it is also not as settled as, say, a hyaluronic acid filler.
These are prescription medical procedures performed by clinicians, with the risk profile any injectable carries.
The Topical Problem
Here is the part that matters most for anyone reading this with a $30 ampoule in their bathroom, and it applies equally to PDRN and PN.
Every piece of clinical evidence described above concerns injection — the molecule placed directly into the dermis, past the barrier entirely. Topical products face the barrier, and these are large molecules. PDRN's fragments are already substantial; PN is high molecular weight by definition, which is precisely the property that makes it useful as an injectable scaffold and precisely the property that makes meaningful penetration through intact stratum corneum implausible.
This does not mean topical PDRN and PN products are useless. DNA-derived polymers are excellent humectants, they form a film that reduces water loss, and formulations built around them are frequently well-made and genuinely hydrating. People who like these products are not imagining the result.
It means the result you are getting is most likely hydration and barrier support, not the regenerative effect demonstrated in the injectable literature. Marketing that cites clinical regeneration data on a topical product page is citing evidence for a different route of administration, and that is the single most common overclaim in this entire category.
Delivery devices change this picture somewhat — electroporation and microneedling are specifically intended to bypass the barrier, and we cover those separately — but a cream applied by hand does not.
What This Means for What You Buy
If you want the regenerative effect the research describes, that is a clinic conversation about injectable PN or PDRN with a qualified practitioner, with the cost and risk profile of a medical procedure.
If you want a good topical product, buy PDRN and PN formulations for what they reliably deliver — hydration, barrier support, and a pleasant texture — and judge them against other well-formulated hydrating serums at the same price rather than against clinic treatments. Many are genuinely excellent on those terms.
Be sceptical of: topical products citing injectable clinical trials; the word 'Rejuran' on a cosmetic product, since that is a specific injectable brand; and premium pricing justified by the ingredient's clinical reputation rather than by the formulation.
And note the concentration question the topical category never answers. Cosmetic PDRN and PN products rarely disclose concentration, and unlike niacinamide or salicylic acid there is no established topical effective dose to compare against — because the effective doses in the literature are injection doses.
Frequently Asked Questions
What's the difference between PN and PDRN?+
Molecular weight and source. PDRN is lower molecular weight DNA fragments, typically from salmon or trout sperm DNA, acting mainly as a biochemical signal through adenosine A2A receptors. PN is a high molecular weight DNA chain from gonads, viscoelastic enough to form a three-dimensional porous structure — so it signals and provides physical scaffolding. That's why PN became Korea's dominant injectable skin booster.
Does topical PDRN or PN work like the injections?+
No, and this is the category's biggest overclaim. All the regenerative clinical evidence concerns injection, past the skin barrier entirely. These are large molecules — PN is high molecular weight by definition — so meaningful penetration through intact stratum corneum is implausible. Topically they work as humectants and film-formers, which is genuinely useful hydration, just not regeneration.
Is Rejuran a skincare product?+
No. Rejuran is an injectable polynucleotide skin booster, launched in 2014, administered by a clinician. The name has become genericised for the PN category the way Botox has for neuromodulators, so seeing it invoked on a cosmetic product page is a marketing borrow rather than a description of what's in the bottle.
Author
Glowstice Editorial
The Glowstice editorial team consists of skincare researchers, cosmetic chemists, and science writers dedicated to translating peer-reviewed dermatology into practical guidance for curious consumers.
